In new draft guidance, the FDA has taken steps to eliminate the clinical testing of biosimilars and to categorize all ...

A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s ...

Picking a date for a press conference in Puerto Rico in the middle of hurricane season can be risky business. | Eli Lilly has ...

Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40-billion-pound sales projection ...

With a physician mother and geologist father, Katie Morris, Ph.D., was immersed in the world of science from a young age. | ...

After a progression-free survival win last year raised hopes for the combo's potential in hepatocellular carcinoma, an overall survival miss brings the study to a close.

Akebia Therapeutics has scrapped plans for trial that would have potentially led to an expansion of the patient population for its new anemia drug Vafseo, the company said.